Prevent Protein Aggregation in Biopharma Formulations

Protein stabilizers tackle one of the most critical challenges in biopharmaceutical production — preventing biomolecule aggregation at every stage of the biopharmaceutical process, formulation and manufacturing. Our products help you maintain the stability and therapeutic activity of your biopharmaceutical products to support consistent manufacturability, extended shelf life, and reliable therapeutic performance.
Key Benefits and Features
High-quality Protein Stabilizers
A portfolio of high-quality sugars, polyols, amino acids, and surfactants to protect your biomolecule from aggregation.
Low Endotoxin and Microbial Levels
Our Emprove® Expert portfolio is designed to meet regulatory requirements for high-risk applications, helping you reduce microbial contamination risks.
Industry-leading Documentation
Emprove® Program and comprehensive documentation to support your risk assessment efforts, including Elemental Impurity Information according to ICH Q3D.
Sugars and Polyols
Sugars and polyols protect the biomolecule against thermally induced instabilities, improving resistance elevated temperatures and temperature shifts during manufacturing, transport and storage.
Amino Acids
When used as excipients in biopharma formulations, amino acids act as protein stabilizers, buffering agents and antioxidants to help maintain product integrity.
Surfactants
To prevent surface or mechanically induced aggregation because of pumping or shaking, surfactants or cyclodextrin can be used to maintain protein integrity.
Viscosity Reduction Platform
In the case of highly concentrated protein formulations, the Viscosity Reduction Platform of proprietary excipient combinations is ideal to reduce viscosity while maintaining protein stability.
Emprove® Expert Portfolio: Meeting Regulatory Requirements of High-risk Applications
Our commitment to advancing pharmaceutical development is backed by the Emprove® Program, which provides comprehensive documentation to expedite your journey to market. For high-risk applications such as parenteral administration, our Emprove® Expert excipient portfolio is particularly well suited as it features specified low endotoxin and bioburden levels to support risk mitigation efforts.
Frequently Asked Questions
What are the main causes of protein aggregation in biopharmaceutical formulations?
The structure of biomolecules, such as monoclonal antibodies and other proteins or peptides, is highly relevant for their therapeutic effect. Under certain conditions, biomolecules are highly susceptible to aggregation and unfolding which leads to reduced stability and a loss of functionality. Elevated temperatures, mechanical stress during manufacturing and transport, extreme pH conditions, and high protein concentrations can lead to partial unfolding of proteins, resulting in self-association and aggregates that compromise therapeutic activity and patient safety.
What strategies can be employed to enhance biomolecule stability in biopharmaceutical formulations?
To enhance biomolecule stability, it is essential to ensure optimal formulation and environmental conditions such as optimal pH, avoiding high and low temperatures, and minimizing shear stress. Using stabilizing excipients like sugars, polyols, and amino acids can protect against thermal and mechanical stress, reducing the risk of protein aggregation during manufacturing, storage and administration.
How do sugars and polyols function as protein stabilizers?
Sugars and sugar alcohols (e.g., sucrose, trehalose, myo-inositol, mannitol) are commonly used as stabilizers in liquid formulations or during lyophilization. During lyophilization, they form a glass matrix that replaces water in hydrogen bonds, maintaining the protein's native structure. In solution, they shift the equilibrium towards the protein’s native folded state by strengthening the hydration shell or binding to the unfolded protein. Read our case study.
What role do surfactants play in preventing protein aggregation?
Proteins can form a film at hydrophobic interfaces, which is susceptible to rupture (e.g. through mechanical stress like shaking of the vial) and subsequent aggregation. Surfactants, such as polysorbates and poloxamers, stabilize proteins by preventing adsorption to these surfaces and binding to hydrophobic sites of the protein molecule. This keeps the protein in solution and lessens its susceptibility to mechanical stress. Learn more in our case study.
How can amino acids contribute to protein stability in formulations?
Amino acids can serve multiple roles in biopharmaceutical formulations, acting as stabilizers, buffering agents, and antioxidants. They help maintain the protein's native structure and can solubilize the biomolecule. Amino acids known for their stabilizing effects include glycine, arginine, histidine and amino acid derivative N-acetyl-DL-tryptophan.
Related Articles
- How to Prevent Protein Aggregation Using Stabilizers and Surfactants
Discover efficient strategies for formulating mRNA, including information on lipid selection, lipid nanoparticles, and excipients for optimal stability.
- Low-in-Nanoparticulate-Impurities Sucrose for Biopharmaceutical Formulations
This article describes a purification process resulting in low nanoparticulate impurities sucrose, enabling more stable protein formulations.
- Formulation Strategies for mRNA Vaccines and Therapeutics
Discover efficient strategies for formulating mRNA, including information on lipid selection, lipid nanoparticles, and excipients for optimal stability.
- Peer-reviewed article: Exploring the Protein Stabilizing Capability of Surfactants Against Agitation Stress and the Underlying Mechanisms
This study compares the protein-stabilizing capacities of poloxamer 188, HPB-cyclodextrin, a trehalose-based surfactant, and polysorbate 80 and explores the mechanisms behind the observed protein aggregation and particle formation reduction.
- Accelerating Biologics Development with High-Quality Protein Stabilization Excipients
Learn from our experts about protein instability and aggregation challenges in biopharmaceutical formulations, and the typical strategy to identify the optimal protein stabilizer solution.
- Securing Protein Stability With Low-NPI Sucrose
Discover how a low in nanoparticle impurities sucrose supports improved stability in biopharmaceutical formulations.
Related Documents
- Flyer: High-Quality Stabilizers for Your Biomolecules
Browse the flyer showcasing key features of our stabilizer portfolio.
- White Paper: Protecting Protein Stability with a Novel Grade of Sucrose
Get insights on NPIs found in commercially available sucrose, their origin and impact on protein stability.
- White Paper: Use of Excipients in Downstream Processing to Improve Protein Purification
Read about the effects of excipients on purification performance in Protein A chromatography and protein stability in virus inactivation.
- White Paper: Optimizing Poloxamer 188 for Use in Liquid Protein Formulation and Cell Culture Applications
Dive into stabilization mechanisms of poloxamer 188 and how to use attributes such as molecular weight and hydrophobicity to select the best option for liquid formulation and cell culture applications.




